Gastric Hypersecretory Conditions — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for gastric hypersecretory conditions. 13 active patents protecting 3 drugs from 3+ originators. First major cliff: 2036. Daily refresh.

3
Approved drugs
13
Active US patents
53/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Gastric Hypersecretory Conditions

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca (originally Astra AB) 10 patents Generic (originally Takeda) 2 patents Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating gastric hypersecretory conditions. Each bar = one year. Y-axis scaled to peak year (7 patents).

1
26
4
36
7
39
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Prilosec
omeprazole
 AstraZeneca (originally Astra AB) 10 37 $1.0B 2036-12-08
Prevacid
lansoprazole
 Generic (originally Takeda) 2 49 — 2036-04-21
Pantoprazole Sodium
Pantoprazole Sodium
 Pfizer 1 73 — 2026-12-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7544370 Pantoprazole Sodium other 80 2026-12-07
11911473 Prilosec method of use 58 2039-07-16
11986554 Prevacid formulation 55 2036-04-21
11771686 Prilosec method of use 53 2040-03-01
11077055 Prevacid formulation 42 2036-04-21
12042539 Prilosec formulation 38 2039-07-16
12440566 Prilosec formulation 38 2039-07-16
12329752 Prilosec formulation 38 2039-07-16
10751333 Prilosec formulation 33 2039-07-16
11103492 Prilosec formulation 33 2039-07-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10835488 Prilosec formulation 25 2036-12-08
10076494 Prilosec formulation 25 2036-12-08
11103492 Prilosec formulation 33 2039-07-16
11633478 Prilosec formulation 33 2039-07-16
10751333 Prilosec formulation 33 2039-07-16
12440566 Prilosec formulation 38 2039-07-16
12329752 Prilosec formulation 38 2039-07-16
12042539 Prilosec formulation 38 2039-07-16
11077055 Prevacid formulation 42 2036-04-21
11771686 Prilosec method of use 53 2040-03-01

Related